[Von Willebrand factor and soluble P-selectin in patients with non ST-Elevation acute coronary syndrome during treatment with glycoprotein IIb/IIIa antagonist eptifibatide].
Soluble P-selectin (marker of activation of platelets) and von Willebrand factor (marker of activation of endothelium) were measured in 44 patients with non ST-Elevation acute coronary syndrome (NSTEACS) 21 of whom received glycoprotein IIb/IIIa antagonist eptifibatide (two 180 mg/kg boluses with 10 min interval followed by infusion of 2 mcg/kg/min during first 24 hours and 1.3 mcg/kg/min during subsequent 48 hours). Measurements were made within first 2 hours, in 2--3 and 10--14 days after development of NSTEACS. During first 2 hours P-selectin content was 1.6 times higher than in healthy donors, but in 2--3 and 10--14 days after onset of NSTEACS it did not differ from normal values. Contrary to P-selectin value of von Willebrand factor was elevated both during first 2 hours (1.3 times) and in 2--3 days (2 times) compared with healthy donors. Some elevation of von Willebrand factor (1.2 times) persisted after 10--14 days after development of NSTEACS. The results obtained have shownd that elevated activity of endothelium persists at least for 2--3 days after onset of NSTEACS, while activity of platelets during this period decreases. In none of temporal points there have been revealed differences in contents of P-selectin and von Willebrand factor between groups of patients receiving and not receiving glycoprotein IIb/IIIa antagonists. No differences were also found between these parameters in groups of patients favorable and unfavorable outcomes (myocardial infarction, angina recurrence) of the disease during 30 days of follow-up.
Mazaev
A A
AA
Naĭmushin
Ia A
IaA
Khaspekova
S G
SG
Golubeva
N V
NV
Ruda
M Ia
MIa
Mazurov
A V
AV
D054058:Acute Coronary Syndrome / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D004730:Endothelium, Vascular / Q000378:metabolism; D000077542:Eptifibatide; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D007262:Infusions, Intravenous; D019007:P-Selectin / Q000097:blood*; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D014841:von Willebrand Factor / Q000378:metabolism*
D019007:P-Selectin; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014841:von Willebrand Factor; D000077542:Eptifibatide